# Genprex, Inc. (GNPX) — delisting/forced [announced]
Source: SEC API (secapi.ai) · situation sit_3ed777c9cd60af71e7b6 · retrieved 2026-08-11T16:12:01.751Z

## Overview
Genprex, Inc. is a pharmaceutical preparations company (SIC 2834) based in Austin, Texas.

On August 4, 2026, Genprex, Inc. was formally notified by the Nasdaq Hearings Panel that it has regained compliance with the $1.00 Minimum Bid Price requirement under Nasdaq Listing Rule 5550(a)(2). The Panel will maintain jurisdiction over the Company until December 7, 2026, during which time Genprex must maintain a closing bid price at or above $1.00 for each trading day. If the Company becomes non-compliant with any other Listing Rule between now and December 7, 2026, it will be allowed seven calendar days to advise the Panel on its plan to cure the deficiency, after which the Panel will determine whether to grant an exception or delist the Company.

## Terms
- Counterparty: Nasdaq Hearings Panel · Price/share: $1

## Key dates
- Announced 2026-07-30 · Expiry 2026-12-07

## Timeline
- 2026-07-30 · 8-K (0001437749-26-025074): 8-K - Genprex, Inc. — *Genprex, Inc. is a pharmaceutical company developing gene therapy and immunotherapy product candidates.* On July 29, 2026, the Nasdaq Hearings Panel granted Genprex, Inc. an exception to continue its listing on The Nasdaq Capital Market after the company failed to maintain the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The company must demonstrate compliance with the bid price requirement on or before July 29, 2026, and thereafter maintain a closing bid price at or above $1.00 for each trading day until December 7, 2026. The Panel will maintain jurisdiction over the company until December 7, 2026, and has reserved the right to reconsider the exception terms based on any event that would make continued listing inadvisable. The company implemented a one-for-twenty-two (1:22) reverse stock split effective July 16, 2026 in an effort to regain compliance with the bid price requirement.
  https://www.sec.gov/Archives/edgar/data/1595248/0001437749-26-025074.txt
- 2026-08-05 · 8-K (0001437749-26-025938): 8-K - Genprex, Inc. — *Genprex, Inc. is a pharmaceutical preparations company (SIC 2834) based in Austin, Texas.* On August 4, 2026, Genprex, Inc. was formally notified by the Nasdaq Hearings Panel that it has regained compliance with the $1.00 Minimum Bid Price requirement under Nasdaq Listing Rule 5550(a)(2). The Panel will maintain jurisdiction over the Company until December 7, 2026, during which time Genprex must maintain a closing bid price at or above $1.00 for each trading day. If the Company becomes non-compliant with any other Listing Rule between now and December 7, 2026, it will be allowed seven calendar days to advise the Panel on its plan to cure the deficiency, after which the Panel will determine whether to grant an exception or delist the Company.
  https://www.sec.gov/Archives/edgar/data/1595248/0001437749-26-025938.txt

## Citations
- 0001437749-26-025074 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000143774926025074
- 0001437749-26-025938 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000143774926025938